DGAP-Adhoc: Biotest AG: Altered Tax Assessments for 2005 -

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 3, 2016 at 12:30 PM

DGAP-Adhoc: Biotest AG: Altered Tax Assessments for 2005 - 2008

Biotest AG / Key word(s): Legal Matter 03.08.2016 18:15 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered Tax Assessments for 2005 - 2008 Dreieich, 3 August 2016. Today the Finanzamt Offenbach am Main (tax office Offenbach am Main) served to Biotest AG altered tax assessments for corporate tax, solidarity tax and trade tax for the years 2005 until 2008. The alterations are based on the investigations by the tax authorities and the public prosecutor in connection with the Russia business of Biotest AG. This leads to liabilities for tax and interest totalling to approx. EUR 20 million. The company will have the tax assessments evaluated by their tax consultants. According to our first appraisal this approach by the financial authorities is conflicting with recently published decisions by the Bundesfinanzhof (Federal Fiscal Court) on the tax deduction of operating expenses. Biotest Aktiengesellschaft Board of Management Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,300 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. IR contact Dr. Monika Buttkereit phone: +49-6103-801-4406 email: investor_relations@biotest.de PR contact Dirk Neumüller phone: +49-6103-801-269 email: pr@biotest.de Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Preference shares: securities' ID No. 522723; ISIN DE0005227235 Listing: Prime Standard Open Market: Berlin, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart 03.08.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ICAC's Landmark Program Strengthens Africa's Anti-Corruption Efforts

A Bold Step Towards Integrity Corruption has long been a thorn in the side of progress for many regions, and watching the Hong Kong International Academy Against Corruption (HKIAAC) step up to the plate in Africa feels like a much-needed move. I mean, when you've got the collective wisdom of folks who've been through the wringer on these issues, you'd be wise to pay heed....

Hyliion Faces Legal Whirlwind After Stock Tumbles 19.3%

Battered by Allegations: Hyliion in Legal Crosshairs Here's a hot mess Hyliion's found itself in. Amidst allegations of deception, the stock has dropped a hefty 19.3%. For anyone keeping tabs on this one, the legal eagles over at The Law Offices of Frank R. Cruz have swooped in, announcing a class action that's got all the trimmings of your classic securities mess. The...

Ardelyx Investors Face Lawsuit Over Misleading Claims

Investors Land in Hot Water with Ardelyx Alright, folks, here we go again. New York's courtroom dramas are in full swing with Ardelyx, Inc. at center stage, and not in a good way. The DJS Law Group has rallied the troops, reminding investors caught in the storm of a class action lawsuit. Specifically, it's all about alleged violations of the Securities Exchange Act of...

Suunto Unleashes High-Tech Race 3S Watch with AI Coach

The Latest in Performance Gear: Suunto's Race 3S Nobody wants their gear to be a limitation, especially out in the wild where every step counts. Enter Suunto's Race 3S—a watch that looks to change the game for those passionate about trail running. This gadget's packed with features meant for athletes who are serious about their tech, yet light enough to make you forget...

Anita Eno: 2027's Top Trailblazing Businesswoman

Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...

Minesto Joins Sweden-Indonesia Partnership in Energy Shift

Minesto's Big Splash in Indonesia's Energy Transition Here we go, folks. Minesto's taking the plunge into Indonesia's uncharted tidal waters under a Sweden-backed partnership. This Swedish underdog in ocean energy is ready to shake things up and ride the Indonesian currents, thanks to the Sweden-Indonesia Sustainability Partnership. Now, why should this matter to you, the...

NVIDIA GTC Unveils Fleet's New AI Device Support

Expanding the AI Frontier: Fleet Meets NVIDIA NVIDIA just pulled a major move at their GTC Berlin event, rolling out a comprehensive suite of device management for their AI hardware ecosystem through Fleet. Picture this: IT folks can now handle NVIDIA’s flagship AI gear alongside all those pesky other devices without losing their minds or sleep. From RTX PRO...

PuroClean Shines in Franchise Rankings with Global Growth

Diversifying with Property Restoration Stroll through any franchise expo and the buzzwords are all there: growth, opportunity, scalability. But in the crowded room of glittery pitches, the ones really shaking things up are those that go beyond the razzle-dazzle—brands like PuroClean that stick it to the competition with real, boots-on-the-ground expansion. The...

Plaid Eyes Data Horizons; Acorns Embraces Gen Z

Fintech's Next Frontier: Plaid's Vision You ever get the feeling some folks see further down the road than others? That's Plaid CTO Will Robinson, chatting up the NYSE folks at Money20/20. The man’s got his eyes on what he calls "making sense" of financial data—no small feat in our swamped digital world. Plaid ain't some penny stock operation, either. This is an $8...

Hengrui Pharma at ESMO 2026: Innovations in Oncology

Pushing Boundaries at ESMO 2026 If there's one place where the future of cancer treatment is being etched out, it's at forums like the ESMO Congress. This year, Hengrui Pharma is rolling in with 64 research findings hotter than a two-dollar pistol, all set to make waves in oncology. From breast to lung cancer, they're covering the lot and showcasing a blend of established...